Delcath Systems, Inc.

    Jurisdiction
    United States
    LEI
    549300NVPLITUM6URT02
    ISIN
    US24661P8077 (DCTH)
    Sectors
    1. Healthcare
    2. Medical - Devices

    Scores

    InsiderPie Expert Score
    trending_flat 50 / 100
    Even with peer group:
    50 / 100
    Fair value (Benjamin Graham formula)
    N/A
    Financial strength (Piotroski F-Value)
    8 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    4 / 7

    Profile

    Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. Read full profile

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Fundamentals

    Net revenue
    €58.86M
    Gross margin
    87.9%
    EBIT
    €4.30M
    EBIT margin
    7.3%
    Net income
    €1.92M
    Net margin
    3.3%

    Statement period: - (published )

    Estimates

    Fiscal Year Net revenue Net income
    €104.29M +77.2% €16.65M +769.6%
    €133.12M +27.6% €36.95M +121.9%
    €151.22M +13.6% €57.34M +55.2%

    Dividends

    No dividend payouts

    Earnings Calls

    Latest earnings call: May 14, 2024

    Investor transactions

    Name Shares Value Last change Change type
    Peter Brown 71K $907.65K -67K Sell

    Add to watchlist

    Notifications